omniture

Renhuang Pharmaceuticals, Inc.'s Laboratory Recognized by Heilongjiang Science and Technology Institute

2008-07-01 14:57 769


HARBIN, China, July 1 /Xinhua-PRNewswire-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or "the Company"), a leading pharmaceutical company in the People's Republic of China ("PRC"), today announced that its wholly-owned Traditional Chinese Medicine Extract and Innovation Laboratory ("Laboratory") was recognized as a Key Laboratory in Heilongjiang Province by the Science and Technology Institute of Heilongjiang ("the Institute") in China on June 20, 2008.

The Institute is a government supported entity that promotes the development of technology companies and technologically advanced products. Renhuang is honored that its Traditional Chinese Medicine Extract and Innovation Laboratory has been selected as one of seven enterprise key laboratories in Heilongjiang province and is proud of its advanced and professional ability in R&D field as a pharmaceutical enterprise.

With a highly-qualified research and development team in Traditional Chinese Medicine and biology, Renhuang's Laboratory focuses on research of standard extract of Chinese medicine and development of innovative medicine. The management team at Renhuang strongly supports the Laboratory and plans to develop its capabilities further while increasing the scale of the business.

"Renhuang is very excited to receive this prestigious award for its research and development capabilities from the Science and Technology Institute of Heilongjiang," said Mr. Shao-ming Li, Chairman and CEO of Renhuang Pharmaceuticals, Inc. "We will continue to improve our efforts in advanced research and technology and expect to establish the top research and development center for Traditional Chinese Medicine extract and innovation in the world."

About Renhuang Pharmaceuticals, Inc.

Founded in 1996, Renhuang Pharmaceuticals, Inc. produces western, Traditional Chinese Medicines (TCMs), and branded pharmaceuticals using its GMP-certified facilities in China. The Company's GMP-certified manufacturing facilities, which employ cutting-edge technology and advanced equipment, are capable of producing as many as 200 different types of pharmaceuticals. Renhuang also distributes raw materials and finished pharmaceutical products using its extensive distribution channels throughout China, including third party distributors. The Company's distribution network includes over 3,000 sales representatives in 70 sales centers across 24 districts, covering over 50% of greater China. The Company also exports its products to Russia and Southeast Asia. For more information, visit http://www.renhuang.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

Renhuang Pharmaceuticals, Inc.

Ms. Shuang Tan, IR Contact

Tel: +86-451-5392-5461

Email: ir@renhuang.com

CCG Elite Investor Relations Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com, or

Mr. Richard Micchelli, Sr. Financial Writer

Tel: +1-646-454-4516

Email: richard.micchelli@ccgir.com

Web: http://www.ccgelite.com

Source: Renhuang Pharmaceuticals, Inc.
Related Stocks:
AMEX:CBP
collection